Can Autoimmune Hepatitis Cause Elevated White and Red Blood Cell Counts?
Autoimmune hepatitis (AIH) does not typically cause elevated white or red blood cell counts; in fact, the opposite is more common—AIH patients often present with cytopenias (low blood counts) due to hypersplenism from cirrhosis or as a side effect of immunosuppressive treatment. 1
Hematological Abnormalities in AIH
Expected Blood Count Patterns
- Cytopenias are the typical finding in AIH patients, particularly those with advanced disease and cirrhosis with portal hypertension leading to hypersplenism 1
- White blood cell counts below 2.5 × 10⁹/L and platelet counts below 50 × 10⁹/L are common enough that they represent contraindications to starting azathioprine therapy 1
- Moderate leucopenia is common in cirrhosis and does not necessarily increase the risk of azathioprine-related marrow depression, though it complicates monitoring 1
Autoimmune Hemolytic Anemia Association
- AIH can be associated with autoimmune hemolytic anemia (AIHA), though this is rare 2
- When AIHA occurs with AIH, it causes hemolysis and anemia (low red blood cell counts), not elevated red blood cell counts 2
- The association between AIH and AIHA is rarely reported, but both are autoimmune in nature 2
- Measurement of red blood cell-associated IgG is recommended in AIH cases with anemia, even when direct antiglobulin test is negative 2
Red Blood Cell Distribution Width (RDW)
- Elevated RDW (red blood cell distribution width) is associated with more severe liver inflammation in AIH patients 3
- RDW levels correlate positively with grades of liver inflammation (r=0.356, P < 0.001) 3
- This represents increased variation in red blood cell size, not an elevated red blood cell count 3
Treatment-Related Hematological Effects
Immunosuppressive Therapy Impact
- Azathioprine causes myelosuppression, resulting in reduced granulocyte, platelet, and red cell counts 1
- These reductions are usually mild and well-tolerated unless pre-existing hematological problems or hypersplenism exist 1
- Blood counts return to normal after therapy cessation 1
- Regular monitoring of blood counts is mandatory: weekly for 4 weeks, then 1-3 monthly thereafter during treatment 1
TPMT Deficiency Considerations
- Homozygous TPMT (thiopurine methyltransferase) deficiency (approximately 1 in 300 people) leads to accumulation of active metabolites and serious marrow toxicity 1
- TPMT measurement should be considered to exclude homozygous deficiency, particularly in patients with pre-existing leucopenia 1
When to Suspect Alternative Diagnoses
Elevated Blood Counts Should Prompt Investigation For:
- Concurrent hematological malignancies or myeloproliferative disorders (not caused by AIH itself)
- Systemic lupus erythematosus (SLE) overlap: 2.2-2.8% of AIH patients have concurrent SLE, which can present with various hematological abnormalities 1, 4
- Inflammatory bowel disease overlap: occurs in 2-11.4% of AIH patients and may have different hematological profiles 1
- Infection or inflammatory response unrelated to the AIH itself
Important Caveats
- If a patient with AIH presents with elevated white blood cell counts, consider acute infection, steroid-induced leukocytosis, or an unrelated hematological condition 1
- If elevated red blood cell counts are present, this is not a feature of AIH and warrants separate investigation for polycythemia vera or secondary erythrocytosis
- Thrombocytopenia and hemolytic anemia are the autoimmune hematological complications associated with AIH, not thrombocytosis or polycythemia 2
Clinical Monitoring Recommendations
- Baseline complete blood count should be obtained before starting immunosuppressive therapy 1
- Weekly monitoring for 4 weeks, then 1-3 monthly monitoring of blood counts during treatment 1
- Any significant cytopenias may necessitate dose reduction or alternative immunosuppressive agents like mycophenolate 1
- Consider TPMT testing in patients with pre-existing leucopenia before starting azathioprine 1